Genscript Biotech's multiple myeloma-focused spinoff, which counts Eli Lilly and Johnson & Johnson among its investors, has completed an initial public offering in the US.

The online car retailer will float in an upsized offering that represents an exit for AutoNation, having raised more than $720m in venture funding.

Novartis bought $10m in shares as the fibrosis treatment developer floated at the top of its range in an expanded initial public offering.

The female-focused media services provider has listed in Japan, enabling Asahi Broadcasting, AsobiSystem, GMO, Gree, Hakuhodo DY, iStyle, MAK, NEC, Nexyz, Seraku, SoftBank and TBS to exit.

Appliance manufacturer Gree bought $89m of shares in an initial public offering in which the oncology therapy developer floated at the top of its range.

The Mandatum Life and Ilmarinen-backed nanoparticle technology developer has priced a $76.7m offering that will take place in Sweden and Finland.

The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.

The AstraZeneca cancer drug spinoff floated above its range in an upsized initial public offering and now has a market cap topping $2bn.

Kingsoft’s cloud services subsidiary priced shares at the middle of the range but upsized the offering to raise $510m, with shares soaring 27% on the first day of trading.

The mobile payment terminal supplier booked $5.8m from its IPO and is now lining up an acquisition to expand its business.